ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Recruiting · NCT06597721 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2026-09-09 | NCT06597721 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Adcendo ApS | 3 |
14 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cabrini Hospital | Malvern | Australia | 12 |
| Highlands Oncology Group | Rogers | United States | 7 |
| Linear Clinical Research | Nedlands | Australia | 23 |
| Macquarie University Hospital | Macquarie Park | Australia | 10 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Peninsula and South Eastern Haematology and Oncology Group (PSEHOG) | Frankston | Australia | 1 |
| Peter MacCallum Cancer Centre | Melbourne | Australia | 149 |
| Scientia Clinical Research | Randwick | Australia | 20 |
| Southern Oncology Clinical Research Unit | Bedford Park | Australia | 7 |
| START San Antonio | San Antonio | United States | 30 |
| Washington University | St Louis | United States | 182 |
| Yale University Cancer Center | New Haven | United States | 6 |